Management was initiated in accordance with international heart failure guidelines, incorporating angiotensin-converting-enzyme (ACE) inhibitor (ramipril), beta-blocker (bisoprolol), mineralocorticoid receptor antagonist (spironolactone), and SGLT2 inhibitor (dapagliflozin) [9]. The gene discussed is NR3C2; the disease is heart failure.